Patents by Inventor Michael A. Prince
Michael A. Prince has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11990287Abstract: The present disclosure relates to a photovoltaic (PV) device that includes a color-conversion layer that includes at least one of a color-tuning layer and/or an intermediate layer and a photovoltaic layer where the color-conversion layer changes the appearance of the PV device when compared to a similar PV device constructed without the color-conversion layer, the color-conversion layer increases a power output of the PV device by at least one of reflecting light to the PV layer or emitting light which is redirected to the PV layer, and the device is at least partially transparent to light in the visible spectrum.Type: GrantFiled: August 24, 2022Date of Patent: May 21, 2024Assignee: Alliance for Sustainable Energy, LLCInventors: Kevin Joseph Prince, Lance Michael Wheeler
-
Patent number: 11950436Abstract: The present disclosure relates to a device that includes an irregular network of interconnected ridges in physical contact with a planar substrate and a perovskite layer, where the planar substrate include a support layer and a first charge selective contact layer, the first charge selective contact layer is positioned between the support layer and the interconnected ridges, each ridge includes a second charge selective contact layer and an insulating layer, the insulating layer is positioned between the first charge selective contact layer and the second charge selective contact layer, and the perovskite layer substantially covers the plurality of interconnected ridges and the underlying planar substrate.Type: GrantFiled: June 26, 2023Date of Patent: April 2, 2024Assignee: Alliance for Sustainable Energy, LLCInventors: Lance Michael Wheeler, Kevin Joseph Prince, Colin Andrew Wolden, Mirzojamshed M. Mirzokarimov, Christopher Paul Muzzillo
-
Publication number: 20240034797Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.Type: ApplicationFiled: October 6, 2023Publication date: February 1, 2024Inventors: Thomas Emanuel ICHIM, Steven Francis JOSEPHS, Stephen Michael PRINCE, Amir JAFRI, Robert SEGAL, David L. SCHLOTTERBECK
-
Publication number: 20230373369Abstract: Disclosed herein are systems for minimizing the risk of transmission of SARS-CoV-2 and/or other infectious diseases between individuals in close proximity to one another. Said systems may comprise a substantially transparent shield component, a chamber component, and a suctioning component. The systems of the present disclosure are intended to remove any SARS-CoV-2 virus and/or other infectious agents that may be travelling within aerosols.Type: ApplicationFiled: July 30, 2020Publication date: November 23, 2023Inventors: James L. Orrington, II, Michael Prince, Hyunchul Kim
-
Patent number: 11814430Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.Type: GrantFiled: February 12, 2021Date of Patent: November 14, 2023Assignee: IMMUNICOM, INC.Inventors: Thomas Emanuel Ichim, Steven Francis Josephs, Stephen Michael Prince, Amir Jafri, Robert Segal, David L. Schlotterbeck
-
Publication number: 20220410409Abstract: Disclosed herein are mechanical collars comprising a first connecting component and a second connecting component adjoined to one another. The second connecting component may comprise two substantially circular passages, wherein the inner diameter of the first substantially circular passage is larger than the outer diameter of the second substantially circular passage. Also disclosed herein are systems for mitigating the risk of transmission of infectious disease, such as in a healthcare provider's office, comprising mechanical collars as described herein, protective apparatuses, and a mechanical arm such as, without limitation, an articulating mechanical arm. Also disclosed herein are associated methods of mitigating risk of transmission of infectious disease utilizing the mechanical collars and related systems described herein.Type: ApplicationFiled: May 17, 2022Publication date: December 29, 2022Inventors: James L. Orrington, II, Michael Prince, Hyunchul Kim
-
Publication number: 20220409488Abstract: Apparatus, systems, methods and articles are described to prepare and track medications and medication containers as they are prepared, administered to patients and, in some cases, disposed of. Information such as medication type, concentration, and volume are associated with medication containers during preparation and this information can later be consumed/utilized when administering the medication from a container to a patient. Disposing of any remaining medication can also be tracked.Type: ApplicationFiled: September 2, 2022Publication date: December 29, 2022Inventors: Walter John Bochenko, Stephen Michael Prince, Christopher Biagioli
-
Patent number: 11464708Abstract: Apparatus, systems, methods and articles are described to prepare and track medications and medication containers as they are prepared, administered to patients and, in some cases, disposed of. Information such as medication type, concentration, and volume are associated with medication containers during preparation and this information can later be consumed/utilized when administering the medication from a container to a patient. Disposing of any remaining medication can also be tracked.Type: GrantFiled: July 15, 2019Date of Patent: October 11, 2022Assignee: CRISI Medical Systems, Inc.Inventors: Walter John Bochenko, Stephen Michael Prince, Christopher Biagioli
-
Publication number: 20220273470Abstract: An electrode assembly for a myoelectric prosthesis allowing at least partial decoupling of the movement of the at least one electrode from the electrode housing case and from the prosthesis socket through the mounting of the at least one electrode using at least one biasing element. This allows the at least one electrode to be forced into contact with the patient in the target area using a moveable pressure application structure reducing/eliminating socket motion artifacts because the pressure is transferred toward the target area but the at least one electrode is not otherwise constrained to minimise or avoid the at least one electrode being dragged across the target area through the mounting to the prosthesis socket which causes socket motion artifacts.Type: ApplicationFiled: May 19, 2022Publication date: September 1, 2022Inventors: Ali Jabran, David Howard, John Head, Laurence Kenney, Michael Prince
-
Publication number: 20220142269Abstract: Disclosed herein are protective apparatuses for minimizing the risk of transmission of SARS-CoV-2 and other infectious diseases between individuals in close proximity to one another. Said apparatuses may comprise a receiving component comprising a first aperture comprising a series of flanges; as well as a substantially transparent shield component. Protective apparatuses of the present disclosure may be used to protect dentists and other healthcare workers from transmission of infectious agents through aerosols and through transmission of droplets and other bodily fluids that may contain infectious agents and likewise may be used to protect patients in the same manner. Also disclosed herein are systems comprising such protective apparatuses installed to a substantially cylindrical suctioning device such as a vacuum hose or operatively attached to an articulating mechanical arm.Type: ApplicationFiled: November 6, 2020Publication date: May 12, 2022Inventors: James L. Orrington, II, Michael Prince, Hyunchul Kim, McKayla Barber
-
Publication number: 20220041731Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.Type: ApplicationFiled: October 15, 2021Publication date: February 10, 2022Applicant: IMMUNICOM, INC.Inventors: Thomas Emanuel ICHIM, Steven Francis JOSEPHS, Stephen Michael PRINCE, Amir JAFRI, Robert SEGAL, David L. SCHLOTTERBECK
-
Publication number: 20220041730Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment. removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.Type: ApplicationFiled: October 15, 2021Publication date: February 10, 2022Applicant: IMMUNICOM, INC.Inventors: Thomas Emanuel ICHIM, Steven Francis JOSEPHS, Stephen Michael PRINCE, Amir JAFRI, Robert SEGAL, David L. SCHLOTTERBECK
-
Publication number: 20220041729Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.Type: ApplicationFiled: October 15, 2021Publication date: February 10, 2022Applicant: IMMUNICOM, INC.Inventors: Thomas Emanuel ICHIM, Steven Francis JOSEPHS, Stephen Michael PRINCE, Amir JAFRI, Robert SEGAL, David L. SCHLOTTERBECK
-
Publication number: 20220041732Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.Type: ApplicationFiled: October 15, 2021Publication date: February 10, 2022Applicant: IMMUNICOM, INC.Inventors: Thomas Emanuel ICHIM, Steven Francis JOSEPHS, Stephen Michael PRINCE, Amir JAFRI, Robert SEGAL, David L. SCHLOTTERBECK
-
Publication number: 20210198362Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.Type: ApplicationFiled: February 15, 2021Publication date: July 1, 2021Applicant: IMMUNICOM, INC.Inventors: Thomas Emanuel ICHIM, Steven Francis JOSEPHS, Stephen Michael PRINCE, Amir JAFRI, Robert SEGAL, David L. SCHLOTTERBECK
-
Publication number: 20210163597Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.Type: ApplicationFiled: February 12, 2021Publication date: June 3, 2021Applicant: IMMUNICOM, INC.Inventors: Thomas Emanuel ICHIM, Steven Francis JOSEPHS, Stephen Michael PRINCE, Amir JAFRI, Robert SEGAL, David L. SCHLOTTERBECK
-
Patent number: 10890261Abstract: A valve has a housing defining an inlet and an outlet and a cavity therebetween which receives a valve seat. The valve seat defines a slot which receives a gate. The valve seat is sealingly engaged with the housing, the gate sealingly engages the valve seat and is movable within the slot between an open and a closed position using an actuator. An opening in the housing provides access to the cavity. The valve seat may be removed from the housing through the opening by attaching the valve seat to the gate, thereby attaching the valve seat to the actuator, and withdrawing the gate from the housing using the actuator.Type: GrantFiled: January 22, 2020Date of Patent: January 12, 2021Assignee: Victaulic CompanyInventors: William J. Reilly, Lawrence W. Thau, Jr., Michael Davis, Michael Prince
-
Patent number: D958976Type: GrantFiled: February 26, 2021Date of Patent: July 26, 2022Assignee: James L. Orrington, II D.D.S., P.C.Inventors: James L. Orrington, II, Michael Prince, Hyunchul Kim
-
Patent number: D964556Type: GrantFiled: February 26, 2021Date of Patent: September 20, 2022Assignee: James L. Orrington, II D.D.S., P.C.Inventors: James L. Orrington, II, Michael Prince, Hyunchul Kim, McKayla Barber
-
Patent number: D1022923Type: GrantFiled: March 4, 2021Date of Patent: April 16, 2024Assignee: MECHOSHADE SYSTEMS, LLCInventors: Stephen P. Hebeisen, Michael Prince, Hyunchul Kim, Jeremy Dennis, Parth Mukesh Bhatt